Prognostic factors in chronic myeloid leukaemia

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 343-353

  Hernández Boluda, Juan Carlos ^a   Cervantes, Francisco ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

chronic myeloid leukaemia; imatinib; prognosis; tyrosine kinase inhibitors

Indexed keywords

BUSULFAN; CRK LIKE PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON;

AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; BASOPHIL; BLAST CELL CRISIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EOSINOPHIL COUNT; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLEEN SIZE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 71849120423     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.04.005     Document Type: Review

References (84)

1. Minot G., Buckman T., and Isaacs R. Chronic myelogenous leukemia. JAMA 82 (1924) 1489-1494
2. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 82 (1993) 398-407
3. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84 (1994) 4064-4077
4. The Italian cooperative study group on chronic myeloid leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330 (1994) 820-825
5. Allan N.C., Richards S.M., Shepherd P.C.A., et al. The UK medical research council's working parties for therapeutic trials in adult leukaemia. Lancet 345 (1995) 1392-1397
6. Chronic myeloid leukemia trialist' collaborative group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89 (1997) 1616-1620
7. Bonifazi F., De Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
8. Guilhot F., Chastang C., Michallet M., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French chronic myeloid leukemia study group. N Engl J Med 337 (1997) 223-229
9. Baccarani M., Rosti G., De Vivo A., et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99 (2002) 1527-1535
10. Lee S.J. Chronic myelogenous leukaemia. Br J Haematol 111 (2000) 993-1009
11. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic bone marrow transplantation. Lancet 352 (1998) 1087-1092
12. Robin M., Guardiola P., Devergie A., et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 19 (2005) 1613-1620
13. Grahtwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long term data and current results: an analysis by the chronic leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91 (2006) 513-521
14. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 106 (2005) 2969-2976
15. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood 111 (2008) 1039-1043
16. Palandri F., Iacobucci I., Martinelli G., et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 26 (2008) 106-111
17. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
18. O'Brien S.G., Guilhot F., Goldman J.M., et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood 112 (2008) [abstract 186]
19. Tura S., Baccarani M., Corbelli G., et al. Staging of chronic myeloid leukemia. Br J Haematol 47 (1981) 105-119
20. Cervantes F., and Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 60 (1982) 1298-1304
21. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood 63 (1984) 789-799
22. Sokal J.E., Baccarani M., Tura S., et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 66 (1985) 1352-1357
23. Sokal J.E., Gomez G.A., Baccarani M., et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 72 (1988) 294-298
24. Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90 (1998) 850-858
25. Sinclair P.B., Nacheva E.P., Leversha M., et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
26. Huntly B.J.P., Reid A.G., Bench A.J., et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
27. Kolomietz E., Al-Maghrabi J., Brennan S., et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
28. Kreil S., Pfirrmann M., Haferlach C., et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 110 (2007) 1283-1290
29. Hasford J., Pfirrmann M., Shepherd P., et al. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon-α. Haematologica 90 (2005) 335-340
30. Hochhaus A., Reiter A., Saussele S., et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95 (2000) 62-66
31. Kluin-Nelemans H.C., Buck G., le Cessie S., et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 103 (2004) 4408-4415
32. Iacobucci I., Rosti G., Amabile M., et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24 (2006) 454-459
33. Marin D., Marktel S., Bua M., et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 17 (2003) 1448-1453
34. Cervantes F., Hernandez-Boluda J.C., Steegmann J.L., et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 88 (2003) 1117-1122
35. Sneed T.B., Kantarjian H.M., Talpaz M., et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100 (2004) 116-121
36. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104 (2004) 1979-1988
37. Cortes J., Talpaz M., Giles F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101 (2003) 3794-3800
38. O'Dwyer M.E., Mauro M.J., Blasdel C., et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103 (2004) 451-455
39. Cortes J., Talpaz M., O'Brien S., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98 (2003) 1105-1113
40. Rosti G., Iacobucci I., Bassi S., et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. Haematologica 92 (2007) 101-105
41. Quintas-Cardama A., Kantarjian H., Talpaz M., et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
42. Merx K., Müller M.C., Kreil S., et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α. Leukemia 16 (2002) 1579-1583
43. Wang L., Pearson K., Ferguson J.E., et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120 (2003) 990-999
44. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
45. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
46. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
47. Huntly B.J.P., Guilhot F., Reid A.G., et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
48. Kim D.H., Popradi G., Sriharsha L., et al. No significance of chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer 113 (2008) 772-781
49. Castagnetti F., Marzocchi G., Luatti S., et al. Deletions of the derivative chromosome 9 do not influence response to imatinib of early chronic phase chronic myeloid leukemia patients. A GIMEMA working party analysis. Blood 108 (2006) [abstract 2112]
50. Müller M.C., Gattermann N., Lahaye T., et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/araC. Leukemia 17 (2003) 2392-2400
51. Zheng C., Haak M., Brors B., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20 (2006) 1028-1034
52. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103 (2006) 2794-2799
53. Frank O., Brors B., Fabarius A., et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 20 (2006) 1400-1407
54. Yong A.S.M., Szydlo R.M., Goldman J.M., et al. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107 (2006) 205-212
55. Mohty M., Yong A.S.M., Szydlo R.M., et al. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110 (2007) 380-383
56. Mc Lean L.A., Gathmann I., Capdeville R., et al. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 10 (2004) 155-165
57. Villuendas R., Steegmann J.L., Pollan M., et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 20 (2006) 1047-1054
58. Crossman L.C., Mori M., Hsieh Y.C., et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 90 (2005) 459-464
59. White D., Saunders V., Lyons A.B., et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106 (2005) 2520-2526
60. White D.L., Saunders V., Dang P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
61. White D.L., Saunders V., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
62. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
63. Dulucq S., Bouchet S., Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112 (2008) 2024-2027
64. Kantarjian H., Talpaz M., O'Brien S., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (2004) 2873-2878
65. Hughes T.P., Branford S., White D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112 (2008) 3965-3973
66. Cortes J., Baccarani M., Guilhot F., et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. Blood 112 (2008) [abstract 335]
67. de Lavallade H., Apperley J.F., and Khorashad J.S. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26 (2008) 3358-3363
68. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
69. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
70. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112 (2008) 4437-4444
71. Hughes T.P., Hochhaus A., Branford S., et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib at 72 mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients with chronic phase chronic myeloid leukemia. Blood 112 (2008) [abstract 334]
72. Branford S., Lawrence R., Grigg A., et al. Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response. Blood 112 (2008) [abstract 2113]
73. Branford S., Rudzki Z., Harper A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly-diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17 (2003) 2401-2409
74. Hughes T., and Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20 (2006) 29-41
75. Press R.D., Love Z., Tronnes A.A., et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients. Blood 107 (2006) 4250-4256
76. Cortes J., Talpaz M., O'Brien S., et al. Molecular response in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11 (2005) 3425-3432
77. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
78. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
79. Guilhot F., Hughes T.P., Cortes J., et al. Imatinib pharmacokinetic exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS]). Blood 112 (2008) [abstract 447]
80. White D., Saunders V., Grigg A., et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockage and predict response in chronic myeloid leukemia. J Clin Oncol 25 (2007) 4445-4451
81. Hochhaus A., Baccarani M., Deininger M., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22 (2008) 1200-1206
82. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546
83. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112 (2008) 516-518
84. Milojkovic D., Bua M., Apperley J.F., et al. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival. Blood 112 (2008) [abstract 332]